Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies

被引:0
|
作者
O'Donovan, Alexander J. [1 ]
Gorelik, Seth [1 ,2 ]
Nally, Laura M. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Bowdoin Coll, Brunswick, ME USA
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
type; 1; diabetes; stage; 2; 3; teplizumab; disease-modifying therapies; ANTI-CD3; MONOCLONAL-ANTIBODY; C-PEPTIDE RESPONSES; DOUBLE-BLIND; ONSET; TEPLIZUMAB; IDENTIFICATION; PATHOGENESIS; USTEKINUMAB; AUTOANTIGEN; INHIBITOR;
D O I
10.3389/fendo.2024.1477101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A new diagnosis of type 1 diabetes (T1D) may be accompanied by numerous lifelong financial, emotional, and physical challenges, thus advancements in therapies that can delay the onset of clinical disease are crucial. T1D is an autoimmune condition involving destruction of pancreatic beta cells leading to insulin deficiency, hyperglycemia, and long-term insulin dependence. The pathogenesis of T1D is classified into stages, with the first signal being the detection of autoantibodies without any glycemic changes. In the second stage, dysglycemia develops without symptoms, and in stage 3, symptoms of hyperglycemia become apparent, and at this time a clinical diagnosis of T1D is made. As a greater understanding of these stages of T1D have evolved, research efforts have been devoted to delaying the onset of clinical disease. To date, only one medication, teplizumab, has been approved by the Food and Drug Administration (FDA) for the treatment of stage 2 T1D. This narrative review present published trials and ongoing research on disease modifying therapies (DMT) in T1D, the mechanisms of action for each therapy, and the stages of T1D that these interventions are being studied.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes
    Mignogna, Carmen
    Maddaloni, Ernesto
    D'Onofrio, Luca
    Buzzetti, Raffaella
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (12) : 1209 - 1219
  • [12] Current and future therapies for type 1 diabetes
    von Scholten, Bernt Johan
    Kreiner, Frederik F.
    Gough, Stephen C. L.
    von Herrath, Matthias
    DIABETOLOGIA, 2021, 64 (05) : 1037 - 1048
  • [13] Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes
    Kashalikar, Prajakta
    Desai, Shivani
    Sanap, Avinash
    Shekatkar, Madhura
    Bhonde, Ramesh
    RECENT ADVANCES IN INFLAMMATION & ALLERGY DRUG DISCOVERY, 2023, 17 (01): : 64 - 70
  • [14] Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
    Greenbaum, Carla
    VanBuecken, Dana
    Lord, Sandra
    DRUGS, 2019, 79 (01) : 43 - 61
  • [15] Immunotherapy of type 1 diabetes - How to rationally prioritize combination therapies in T1D
    Boettler, Tobias
    von Herrath, Matthias
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2010, 10 (12) : 1491 - 1495
  • [16] Immunotherapy in Type 1 Diabetes: Emerging Therapies and Future Directions
    Thakkar, Simran
    Bhattacharya, Saptarshi
    Nagendra, Lakshmi
    Kalra, Sanjay
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2025, 75 (02) : 322 - 324
  • [17] Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
    Herold, Kevan C.
    Gitelman, Stephen E.
    Gottlieb, Peter A.
    Knecht, Laura A.
    Raymond, Ralph
    Ramos, Eleanor L.
    DIABETES CARE, 2023, 46 (10) : 1848 - 1856
  • [18] Recent Advances in Immune-Based Therapies for Type 1 Diabetes
    Schweiger, Darja Smigoc
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (06): : 631 - 645
  • [19] Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review
    LeFevre, James D.
    Cyriac, Sneha L.
    Tokmic, Adna
    Pitlick, Jamie M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (23) : 2099 - 2117
  • [20] Therapies to Preserve β-Cell Function in Type 1 Diabetes
    Ludvigsson, Johnny
    DRUGS, 2016, 76 (02) : 169 - 185